Pre-Annual General Meeting Information • Apr 5, 2017
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
Paris (France), April 5, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today that Onxeo's shareholders are invited to attend the Company's Combined Ordinary and Extraordinary General Meeting which is being held on Wednesday, April 26, 2017 at 10.00 AM CET at Onxeo's headquarters: 49 Boulevard du Général Martial Valin, 75015 Paris, France.
The official notice of the General Meeting was published in the French Republic's Bulletin des Annonces Légales Obligatoires (i.e. the "Bulletin of Mandatory Legal Announcements") on March 22, 2017 and includes the agenda, the draft resolutions, and information on attendance and voting procedures. Under the conditions set out in current legislation, you can find the notice in its full length, together with all other related documents, on Onxeo's website: http://www.onxeo.com/en/investisseurs/assemblee-generale/
The above-mentioned documents are available to shareholders at the company's headquarters and on the Company's website. Shareholders may request to receive the documents by sending their request and postal or email address to Onxeo either by airmail (Direction Financière – 49 Boulevard du Général Martial Valin, 75015 Paris, France), fax (+33 1 45 58 08 81), or email ([email protected])
Onxeo is a biotechnology company developing innovative drugs for the treatment of orphan diseases in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Onxeo's objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare or resistant cancers.
Onxeo's comprehensive portfolio features a broad orphan oncology pipeline, with 3 major products in several on-going preclinical and clinical programs, alone or in combination for various cancer indications.
The Company is headquartered in Paris, France with offices in Copenhagen and in New York, and has approximately 60 employees. Onxeo is listed on Euronext in Paris, France and Nasdaq Copenhagen, Denmark (Ticker: ONXEO, ISIN Code: FR0010095596).
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference Document filed with the AMF on April 29, 2016, which is available on the AMF website (http://www.amf-france.org) or on the company's website (www.onxeo.com).
<
Onxeo Valerie Leroy, Investor Relations [email protected] +33 1 45 58 76 00
Caroline Carmagnol / Simon Derbanne - Alize RP [email protected] +33 6 64 18 99 59 / +33 6 38 16 26 41
Dušan Orešanský / Emmanuel Huynh – NewCap [email protected]
+33 1 44 71 94 92
Investor & Media Relations US Kirsten Thomas / Lee Roth – The Ruth Group [email protected] / [email protected] +1 508 280 6592 / +1 646 536 7012
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.